Login to Your Account

Neurocrine Shares Dumped As FDA Sets Back Indiplon

By Aaron Lorenzo

Wednesday, May 17, 2006
The FDA delayed approving an immediate-release version of the sleep drug indiplon and rejected a modified-release formulation, actions that on Tuesday crushed the stock of Neurocrine Biosciences Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription